 |  | | | | August 4th CEOcast Weekly Newsletter
VOLUME 363 Companies featured in the current edition of the newsletter: CLXS, GNBT, HYTM, ICLK, ILNS, PLKH, TKO, VYTR Last week was a volatile and active week of trade, although the end result wouldn'... Click here for more... | |
|
|
|
| Forbes Medi-Tech, Inc. | | | | Forbes Medi-Tech Achieves "Minimum Bid Price Requirement" for Continued Listing on the Nasdaq Stock Market
Forbes Medi-Tech Inc. announced today that the Company has demonstrated compliance with Nasdaq's Minimum Bid Price Requirement, as evidenced by a closing bid price of $1.00 or more for a minimum of ten consecutive trading days. Accordingly, the Nasdaq Hearings Panel has determined that the Company's shares will continue to be listed on The Nasdaq Stock Market."We believe that our dual-listing on stock markets in both the U.S. and Canada is strategically important to Forbes, and we are pleased to announce our continued listing on The Nasdaq Capital Market," said Charles Butt, President and CEO of Forbes Medi-Tech Inc. "Forbes continues to execute on its business strategy by re-focusing our attention on our revenue-generating nutraceutical business while continuing to seek favourable business development opportunities for our pharmaceutical assets," added Mr. Butt............ | | | | GoldSpring, Inc | | | | GoldSpring Releases Assay Results Which Demonstrate Continuation of Favorable Indications From Drill Program
GoldSpring, Inc. reported today a continuation in the trend of encouraging assay results from its latest four drill holes, numbered 45-48, suggesting expanded depth and surface area of the identified ore body in the Hartford Complex. The Hartford Complex represents less than five percent of the Company's total leases of landholdings in the Comstock Lode."The assays from drill holes 45-48 continue the trend of favorable indications from our 2008 drilling program, suggesting the potential for a broader range of mineralization," said Jim Golden, GoldSpring's Chief Operating Officer. "As a result of these, and other encouraging results obtained from our drilling activity in the Hartford Complex, we have taken steps to accelerate our drilling program. Specifically, we plan to have three drills operating during the third quarter, which may expedite the completion of our drilling program at the Hartford Complex. The completion of the drill program is an essential step in our return to mine production."................ | | | | Vyteris Inc | | | | Vyteris, Inc. Receives $2.5 Million Loan from Ferring Pharmaceuticals, Inc.
Vyteris, Inc. manufacturer of the first FDA-approved active patch transdermal drug delivery system, received $2.5 million principal amount of financing effective on July 9, 2008 from Ferring Pharmaceuticals, Inc. (Ferring), which represented an advance on a potential milestone payment for a Phase II clinical trial of a product for female fertility treatment. The $2.5 million was advanced in the form of a loan and bears interest at the rate of 10 percent per annum. If Ferring elects to proceed with the Phase II trial, the principal amount of the loan will be paid off through application of the Phase II payment which would otherwise be due under the License Agreement between Vyteris and Ferring. This advance payment represents our productive working relationship with Ferring, said Haro Hartounian, president of Vyteris, Inc. We feel that Ferrings advance of the milestone to us, through the loan, is further indication of our progress in our joint clinical development efforts.......... | | |
|
|